| 徐境苹.微量白蛋白尿对亚临床甲状腺功能减退病人心血管死亡率的预测作用[J].安徽医药,2019,23(1):29-32. |
| 微量白蛋白尿对亚临床甲状腺功能减退病人心血管死亡率的预测作用 |
| Role of microalbuminuria in predicting cardiovascular mortality in individuals with subclinical hypothyroidism |
| 投稿时间：2018-03-31 |
| DOI： |
| 中文关键词: 甲状腺功能减退 白蛋白尿 肾小球滤过率 预测 影响因素分析 患病率 死亡率 |
| 英文关键词: Hypothyroidism Albuminuria Glomerular filtration rate Forecasting Root cause analysis Prevalence Mortality |
| 基金项目: |
|
| 摘要点击次数: 1993 |
| 全文下载次数: 616 |
| 中文摘要: |
| 目的 探究微量白蛋白尿对患有亚临床甲状腺功能减退病人的心血管死亡率的预测作用。方法 2007年2月至2012年2月期间,青海省心血管病专科医院收治了340例肾功能正常且年龄大于40岁病人。病人分为四组:(1)无亚临床甲状腺功能减退且无微量白蛋白尿:无SCH和无MUA；(2)无亚临床甲状腺功能减退,仅有微量白蛋白尿:只有MUA；(3)仅有亚临床甲状腺功能减退,无微量白蛋白尿:只有SCH；(4)既有亚临床甲状腺功能减退又有微蛋白血尿:既有SCH又有MUA。结果MUA在亚临床甲状腺功能减退症病人中发生率为21.0％,而在无亚临床甲状腺功能减退病人中仅为16.4％(P=0.03)。在无SCH和无MUA队列中,亚临床甲状腺功能减退症是MUA的重要独立预测因子(未校正OR=1.75,95％CI:1.24[KG-*3]~2.48,P=0.002；校正OR=1.83,95％CI:1.2[KG-*3]~2.79,P=0.006)。无论病人有无亚临床甲状腺功能减退症,MUA均可作为所有原因死亡率(只有MUA的病人:校正HR=1.43,95％CI:1.3[KG-*3]~1.59,P<0.001；亚临床甲状腺功能减退的病人:校正HR=1.89,95％CI:1.26[KG-*3]~2.81,P=0.002)和心血管死亡(只有MUA的病人:校正HR=1.64,95％CI:1.41[KG-*3]~1.91,P<0.001；亚临床甲状腺功能减的病人:校正HR=1.96,95％CI:1.07[KG-*3]~3.6,P=0.03)的独立预测因子。结论 正常肾功能的亚临床甲状腺功能减退病人的MUA患病率较高。在既有SCH又有MUA组的病人与只有SCH组的病人相比较,前者心血管死亡的风险更高。需要将来的随机对照试验来评估治疗MUA亚临床甲状腺功能减退症的作用及其对心血管事件的影响。 |
| 英文摘要: |
| Objective To explore the role of microalbuminuria (MUA) as a predictor of long term cardiovascular mortality (CVM) in population with and without subclinical hypothyroidism with normal kidney function.Methods From February 2007 to February 2012,340 patients with normal renal function and less than 40 years of age were admitted to our hospital.Patients were categorized into 4 groups:(1) No subclinical hypothyroidism and MUA,(2) MUA,with no subclinical hypothyroidism,(3) Subclinical hypothyroidism,with no MUA,and (4) both Subclinical hypothyroidism and MUA.Results Prevalence of MUA in the subclinical hypothyroid cohort was 21% compared to 16.4% in those without subclinical hypothyroidism (P=0.03).Subclinical hypothyroidism was a significant independent predictor of MUA (n=6 812),after adjusting for traditional risk factors (unadjusted OR-1.75,95% CI-1.24-2.48,P=0.002；adjusted OR-1.83,95% CI-1.2-2.79,P=0.006).Microalbuminuria was a significant independent predictor of long-term all-cause (Adjusted HR-1.7,95% CI-1.24-2.33) and CVM (Adjusted HR-1.72,95% CI-1.07-2.76) in subclinical hypothyroid individuals.Conclusions In a cohort of subclinical hypothyroid individuals,presence of MUA predicts increased risk of CVM as compared to non-microalbuminurics with subclinical hypothyroidism.Further randomized trials will be needed to assess the benefits of treating microalbuminuric subclinical hypothyroid individuals and impact on CVM. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
